...
机译:FGFR改变高级胆管癌患者BGJ398的II研究
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;
Univ Klinikum Heidelberg Heidelberg Germany;
Univ Klinikum Heidelberg Heidelberg Germany;
Mayo Clin Phoenix AZ USA;
Mayo Clin Phoenix AZ USA;
Massachusetts Gen Hosp Ctr Canc Boston MA USA;
Univ Calif Los Angeles David Geffen Sch Med Los Angeles CA 90095 USA;
Vall dHebron Univ Hosp Barcelona Spain;
Keck Sch Med USC Norris Comprehens Canc Ctr Los Angeles CA USA;
UCSF Helen Diller Family Comprehens Canc Ctr San Francisco CA USA;
Clin Univ St Luc Brussels Belgium;
Natl Canc Ctr Singapore Singapore Singapore;
Seoul Natl Univ Seoul South Korea;
Karmanos Canc Inst Detroit MI USA;
Natl Inst Canc Res Tainan Taiwan;
Mahidol Univ Ramathibodi Hosp Bangkok Thailand;
Univ Hosp Gasthuisberg Leuven Belgium;
Natl Taiwan Univ Hosp Ctr Canc Taipei Taiwan;
Ohio State Univ Wexner Med Ctr Columbus OH 43210 USA;
Univ Calif Los Angeles David Geffen Sch Med Los Angeles CA 90095 USA;
Novartis Pharmaceut E Hanover NJ USA;
Novartis Pharmaceut E Hanover NJ USA;
Novartis Pharmaceut E Hanover NJ USA;
Novartis Pharmaceut E Hanover NJ USA;
Massachusetts Gen Hosp Ctr Canc Boston MA USA;
Mem Sloan Kettering Canc Ctr 1275 York Ave New York NY 10021 USA;
Mayo Clin Phoenix AZ USA;
机译:FGFR改变高级胆管癌患者BGJ398的II研究
机译:吉西他滨单独或与顺铂联用于晚期或转移性胆管癌或其他胆道肿瘤的患者:一项多中心随机II期研究| [ndash] |英国ABC-01研究
机译:晚期肝门周围胆管癌(ALPACA)患者不可逆电穿孔消融:多中心I / II期可行性研究方案
机译:在第三阶段研究中,在开放角度荧光眼和OHT患者中无防腐型TaFluprost和蒂莫尔的疗效分析
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:BGJ398在FGFR改变的晚期胆管癌患者中的II期研究
机译:Infigratinib与Gemcitabine Plus Cisplatin多中心,开放式标签,随机,第三阶段III研究,患有FGFR2基因融合的胆管癌/换档患者:验证试验